TPPP and multiple system atrophy: Treatment with novel small-molecule 20S proteasome enhancers (10 μM for 3 h) prevented TPPP/p25α-induced αSyn fibrillization, proteasome impairment, and cell cytotoxicity, indicating a potential new therapeutic strategy to treat TPPP/p25α/αSyn-associated pathologies, such as those found in MSA [96].